Option A
Invest in Research Projects
Direct Project Funding & IP Rights
Direct capital allocation into high-impact, vetted R&D projects across our seven research disciplines — Life Sciences, Information Technology & AI, Physics & Engineering, Sustainability & Energy, Exploration, Facility Usage, and Creation Science.
IP Ownership Model
- Maximum 50% IP allocation to investors. Fund 100% of a project's target and you secure 50% of the resulting IP rights, licensing revenues and royalties.
- Pro-rata scaling. Partial funding scales your IP equity proportionally — funding 50% of the capital target grants 25% IP ownership.
- Fixed institutional retainers. Vertex Catalyst Group always retains 30% of the IP; the Lead Researcher / Research Group retains 20%.
IP & Patent Cost Allocation
- Initial project investment strictly funds research, lab operations, materials and execution.
- IP / patent / trademark prosecution and registration costs are separate and evaluated upon project completion.
- Upon consensus on the commercialization pathway, filing / registration costs are shared 70% by the Project Investor(s) and 30% by Vertex Catalyst Group.
Enter Funder Portal / View Open Projects →
Option B
Invest in Vertex Catalyst Group LLC
Corporate Private Equity & Membership Units
Acquire private equity membership units directly in Vertex Catalyst Group LLC (our sovereign IP holding and commercialization vehicle) — gaining diversified exposure across our entire translational research portfolio rather than being tied to a single project.
Highlights
- Broad Portfolio Diversification: Direct exposure across our full spectrum of defensible intellectual property, deep-tech hardware platforms (including the Nexus Bio-Bridge), life science formulations, and emerging commercial spin-offs.
- Predictable Commercialization Pipeline: Systematic intake and acceleration of 10+ high-rigor translational R&D initiatives annually, targeting a minimum of 2+ defensible commercial patents and spin-offs per year.
- Sovereign Royalty & Licensing Cash Flow: Pro-rata participation in commercial technology licensing agreements, sovereign IP royalty distributions, non-dilutive grant matching, and long-term liquidity events.
- Capital-Efficient Ecosystem: Headquartered in Greenville, South Carolina, maximizing regional and federal non-dilutive innovation funding to de-risk capital deployment.
Inquire About Private Equity →